What Researchers Did
Researchers conducted a double-blind randomized controlled trial involving 49 patients with chronic multiple sclerosis to evaluate the effect of hyperbaric oxygen therapy over four weeks.
What They Found
The study found no objective improvement in clinical, neurophysiological, or immunological parameters across all three groups, including the 49 patients receiving hyperbaric oxygen or control. While some patients subjectively reported feeling better, this was equally observed in both the treated groups and the control group, indicating no specific benefit from hyperbaric oxygen.
What This Means for Canadian Patients
Canadian patients with chronic multiple sclerosis should be aware that this study found no objective benefit from hyperbaric oxygen therapy. Current evidence suggests that hyperbaric oxygen is not an effective treatment for improving clinical outcomes, neurophysiology, or immunology in this patient population.
Canadian Relevance
This study was conducted in France and has no direct Canadian connection.
Study Limitations
The study's relatively small sample size of 49 patients and its specific treatment protocols may limit the generalizability of its findings.